| 000 | 01902 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515031603.0 | ||
| 264 | 0 | _c20061102 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a0006-4971 | ||
| 024 | 7 |
_a10.1182/blood-2006-04-017921 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStein, Rhona | |
| 245 | 0 | 0 |
_aCharacterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. _h[electronic resource] |
| 260 |
_bBlood _cOct 2006 |
||
| 300 |
_a2736-44 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 | _aAntibody-Dependent Cell Cytotoxicity |
| 650 | 0 | 4 | _aApoptosis |
| 650 | 0 | 4 |
_aBurkitt Lymphoma _ximmunology |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aCell Proliferation |
| 650 | 0 | 4 |
_aComplement System Proteins _xmetabolism |
| 650 | 0 | 4 | _aCytotoxicity, Immunologic |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHLA-DR Antigens _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xadministration & dosage |
| 650 | 0 | 4 |
_aLymphoma _ximmunology |
| 650 | 0 | 4 |
_aLymphoma, B-Cell _ximmunology |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 | _aNeoplasm Transplantation |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 | _aTransplantation, Heterologous |
| 700 | 1 | _aQu, Zhengxing | |
| 700 | 1 | _aChen, Susan | |
| 700 | 1 | _aSolis, David | |
| 700 | 1 | _aHansen, Hans J | |
| 700 | 1 | _aGoldenberg, David M | |
| 773 | 0 |
_tBlood _gvol. 108 _gno. 8 _gp. 2736-44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2006-04-017921 _zAvailable from publisher's website |
| 999 |
_c16372881 _d16372881 |
||